Tarsa Therapeutics raises $28M in capital

Tarsa Therapeutics Inc., a Philadelphia drug development firm, raised $28 million from four venture capital firms.
The company is preparing to file a New Drug Application with the U.S. Food and Drug Administration later this year to seek approval for an osteoporosis treatment called Ostara.
Tarsa, which has 12 full-time employees in its Center City offices, has raised a total of $76.6 million since its founding in the fall of 2009.
Foresite Capital was the lead investor in the latest equity financing for Tarsa, which also received funds from current investors Novo A/S, MVM Life Science Partners and Philadelphia’s Quaker Partners.